Table 2.

Clinical and biochemical features of patients with Laron Syndrome.

	Age	Gender	Birth weight (kg)	Birth length (cm)	Weight SDS	Height SDS	Basal GH (ng/ml)	Peak GH (ng/ml)	IGF-1 (ng/ml)	IGF-1 SDS	IGFBP3 (mg/L)	Bone age retardation (months)	GH treatment and duration	ΔHeight after rhGH (cm)
P1	7.6	Male	2.65	Unknown	-2.96	-5.49	15.44	23.36	32	-3.0	1.2 (1.3~5.6)	12	Yes, 0.053mg/kg/d for 2 months	3.3
P2	3.5	Male	3.15	46	-2.93	-2.80	2.10	Unknown	<25	-3.0	Unknown	6	No
P3	14.3	Male	Unknown	Unknown	-2.61	-6.71	9.60	31.7	<25	-3.0	0.6 (0.7~3.9)	28	No
P4	4.8	Male	3.20	51	-1.82	-3.95	1.59	>33.80	<25	-3.0	1.14 (1.0~4.7)	24	Yes, 0.057mg/kg/d for 32 months	17.8

SDS, standard deviation score; rhGH, recombinant human growth hormone.